Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0002657
UniProt IDQ16585
Primary gene name(s)SGCB
Synonym gene name(s)unknown
Protein nameBeta-sarcoglycan
Protein functionComponent of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.
Subcellular locationCell membrane, sarcolemma {ECO:0000250};
Single-pass type II membrane protein {ECO:0000250}. Cytoplasm, cytoskeleton {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q16585
Gene Ontology
(Biological Process)
Complete annatation
cardiac muscle cell development [GO:0055013];
membrane organization [GO:0061024];
muscle fiber development [GO:0048747];
muscle organ development [GO:0007517];
vascular smooth muscle cell development [GO:0097084]
Gene Ontology
(Molecular Function)
Complete annatation
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytoskeleton [GO:0005856];
dystrophin-associated glycoprotein complex [GO:0016010];
integral component of plasma membrane [GO:0005887];
sarcoglycan complex [GO:0016012];
sarcolemma [GO:0042383]
Protein-protein interaction112341
Phylogenetic treeQ16585
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.2918074267677930.5366263588397570.650372505663623
AZA vs. DISU-0.05754292262735590.8224664471419430.98478550430575
AZA vs. IL70.1063563511934840.5889972168590950.999311006273513
AZA vs. SAHA-0.03321903639376730.893553214892320.976874050805
DISU vs. CD3-0.3617655667550160.4384807581255330.569798185171059
DISU vs. IL70.155480640993390.5419029948657680.850049733824155
DISU vs. SAHA0.02466292894216940.9331792249492770.98436042668566
DMSO vs. AZA-0.1337157860014680.4408882766188291
DMSO vs. CD3-0.4370903234777820.3474214359517390.461416666646783
DMSO vs. DISU-0.0781157687988510.75220911303580.969857060964769
DMSO vs. IL70.2473350930899810.1801796082274320.690619779819103
DMSO vs. SAHA0.09291203920720510.6984505851733120.908668271137394
HIV vs. Mock in Activation-0.07523730166787730.9426322098509930.999983755607037
HIV vs. Mock in Latency-0.1333094945345530.4311878223653160.999834320637052
IL7 vs. CD3-0.1756553659750920.7125800909924490.805755417218993
SAHA vs. CD3-0.3510006997678480.4629679775534940.574788398844763
SAHA vs. IL7-0.1444060157789060.5589167301787690.769703776712027
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.245354 0.0956318
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat downregulates 18051367

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa05410 Hypertrophic cardiomyopathy (HCM) - Homo sapiens (human)
hsa05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo sapiens (human)
hsa05414 Dilated cardiomyopathy - Homo sapiens (human)
hsa05416 Viral myocarditis - Homo sapiens (human)